View in EDS

MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma.

Saved in:
Bibliographic Details
Title: MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma.
Authors: Stroh J; Department of Medicine III, Klinikum rechts der Isar, and.; TranslaTUM, Center for Translational Cancer Research, Technical University of Munich, Munich, Germany., Seckinger A; Department of Hematology and Immunology, Myeloma Center Brussels, and.; Labor für Myelomforschung, Vrije Universiteit Brussel (VUB), Jette, Belgium., Heider M; Department of Medicine III, Klinikum rechts der Isar, and.; TranslaTUM, Center for Translational Cancer Research, Technical University of Munich, Munich, Germany., Rudelius M; Institute of Pathology, Ludwigs Maximilians University, Munich, Germany., Eichner R; Department of Medicine III, Klinikum rechts der Isar, and.; TranslaTUM, Center for Translational Cancer Research, Technical University of Munich, Munich, Germany., Schick M; Department of Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin, Berlin, Germany., Slawska J; Department of Medicine III, Klinikum rechts der Isar, and.; Department of Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin, Berlin, Germany., Emde-Rajaratnam M; Department of Hematology and Immunology, Myeloma Center Brussels, and.; Labor für Myelomforschung, Vrije Universiteit Brussel (VUB), Jette, Belgium., Salwender H; Asklepios Tumorzentrum Hamburg, Hamburg, Germany.; AK Altona, Hamburg, Germany.; AK St. Georg, Hamburg, Germany., Bertsch U; Department of Internal Medicine V, and., Goldschmidt H; Department of Internal Medicine V, and.; National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany., Weisel K; Department of Medicine II, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Scheid C; Department of Internal Medicine I, and.; Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany., Keller U; Department of Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin, Berlin, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany; and.; Max-Delbrück Center for Molecular Medicine, Berlin, Germany., Hose D; Department of Hematology and Immunology, Myeloma Center Brussels, and.; Labor für Myelomforschung, Vrije Universiteit Brussel (VUB), Jette, Belgium., Bassermann F; Department of Medicine III, Klinikum rechts der Isar, and.; TranslaTUM, Center for Translational Cancer Research, Technical University of Munich, Munich, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany; and.
Source: Blood advances [Blood Adv] 2022 Jan 25; Vol. 6 (2), pp. 515-520.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 34768284
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Stroh+J%22">Stroh J</searchLink>; Department of Medicine III, Klinikum rechts der Isar, and.; TranslaTUM, Center for Translational Cancer Research, Technical University of Munich, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Seckinger+A%22">Seckinger A</searchLink>; Department of Hematology and Immunology, Myeloma Center Brussels, and.; Labor für Myelomforschung, Vrije Universiteit Brussel (VUB), Jette, Belgium.<br /><searchLink fieldCode="AU" term="%22Heider+M%22">Heider M</searchLink>; Department of Medicine III, Klinikum rechts der Isar, and.; TranslaTUM, Center for Translational Cancer Research, Technical University of Munich, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Rudelius+M%22">Rudelius M</searchLink>; Institute of Pathology, Ludwigs Maximilians University, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Eichner+R%22">Eichner R</searchLink>; Department of Medicine III, Klinikum rechts der Isar, and.; TranslaTUM, Center for Translational Cancer Research, Technical University of Munich, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Schick+M%22">Schick M</searchLink>; Department of Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Slawska+J%22">Slawska J</searchLink>; Department of Medicine III, Klinikum rechts der Isar, and.; Department of Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Emde-Rajaratnam+M%22">Emde-Rajaratnam M</searchLink>; Department of Hematology and Immunology, Myeloma Center Brussels, and.; Labor für Myelomforschung, Vrije Universiteit Brussel (VUB), Jette, Belgium.<br /><searchLink fieldCode="AU" term="%22Salwender+H%22">Salwender H</searchLink>; Asklepios Tumorzentrum Hamburg, Hamburg, Germany.; AK Altona, Hamburg, Germany.; AK St. Georg, Hamburg, Germany.<br /><searchLink fieldCode="AU" term="%22Bertsch+U%22">Bertsch U</searchLink>; Department of Internal Medicine V, and.<br /><searchLink fieldCode="AU" term="%22Goldschmidt+H%22">Goldschmidt H</searchLink>; Department of Internal Medicine V, and.; National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Weisel+K%22">Weisel K</searchLink>; Department of Medicine II, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.<br /><searchLink fieldCode="AU" term="%22Scheid+C%22">Scheid C</searchLink>; Department of Internal Medicine I, and.; Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany.<br /><searchLink fieldCode="AU" term="%22Keller+U%22">Keller U</searchLink>; Department of Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin, Berlin, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany; and.; Max-Delbrück Center for Molecular Medicine, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Hose+D%22">Hose D</searchLink>; Department of Hematology and Immunology, Myeloma Center Brussels, and.; Labor für Myelomforschung, Vrije Universiteit Brussel (VUB), Jette, Belgium.<br /><searchLink fieldCode="AU" term="%22Bassermann+F%22">Bassermann F</searchLink>; Department of Medicine III, Klinikum rechts der Isar, and.; TranslaTUM, Center for Translational Cancer Research, Technical University of Munich, Munich, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany; and.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101698425%22">Blood advances</searchLink> [Blood Adv] 2022 Jan 25; Vol. 6 (2), pp. 515-520.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Hematology%22">American Society of Hematology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101698425 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2473-9537 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2224739529%22">24739529 </searchLink><i>NLM ISO Abbreviation: </i>Blood Adv <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=34768284
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1182/bloodadvances.2021005532
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 515
    Titles:
      – TitleFull: MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Stroh J
      – PersonEntity:
          Name:
            NameFull: Seckinger A
      – PersonEntity:
          Name:
            NameFull: Heider M
      – PersonEntity:
          Name:
            NameFull: Rudelius M
      – PersonEntity:
          Name:
            NameFull: Eichner R
      – PersonEntity:
          Name:
            NameFull: Schick M
      – PersonEntity:
          Name:
            NameFull: Slawska J
      – PersonEntity:
          Name:
            NameFull: Emde-Rajaratnam M
      – PersonEntity:
          Name:
            NameFull: Salwender H
      – PersonEntity:
          Name:
            NameFull: Bertsch U
      – PersonEntity:
          Name:
            NameFull: Goldschmidt H
      – PersonEntity:
          Name:
            NameFull: Weisel K
      – PersonEntity:
          Name:
            NameFull: Scheid C
      – PersonEntity:
          Name:
            NameFull: Keller U
      – PersonEntity:
          Name:
            NameFull: Hose D
      – PersonEntity:
          Name:
            NameFull: Bassermann F
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 25
              M: 01
              Text: 2022 Jan 25
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 2473-9537
          Numbering:
            – Type: volume
              Value: 6
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: Blood advances
              Type: main
ResultId 1